zileuton

Also known as A-64077, ZYFLO®, Leutrol, N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea, (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea, N-[1-(Benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea

thumb|300px|Abbott Laboratories stock bottle of Zyflo (zileuton) 600 mg tablets (manufactured 1997). Also shown are Zyflo tablets, with one tab broken. Tablets are branded with the Abbott "a" logo and "ZL". Zileuton (trade name Zyflo) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names Zyflo and Zyflo CR. The original immediate-r

Research

826 papers

Zileuton.2012
Zileuton.2006
The ALOX5 inhibitor Zileuton regulates tumor-associated macrophage M2 polarization by JAK/STAT and inhibits pancreatic cancer invasion and metastasis.International immunopharmacology · 2023
Zileuton.2026
Zileuton.Lancet (London, England) · 1996

via PubMed

Wikidata facts

Mass: 236.061949

Show 4 more facts

chemical formula: C₁₁H₁₂N₂O₂S
canonical SMILES: CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
World Health Organisation international non-proprietary name: zileuton
Commons category: Zileuton

Sources (9)

via Wikidata · CC0

~7 min read

Article

15 sections

Contents

Pharmacotherapy
Indications and dosing
Contraindications and warnings
Chemistry
Pharmacokinetics
Adverse effects
Interactions
Drug interactions
Other interactions
Overdose/toxicology
Symptoms
Treatment
See also
References
External links

Although the 600 mg immediate release tablet (Zyflo) and extended release formulation of zileuton are still available (Zyflo CR), the 300 mg immediate release tablet was withdrawn from the U.S. market on February 12, 2008.